Oramed Pharmaceuticals Inc.
NASDAQ:ORMP · NASDAQ Capital Market
+$0.03 today
Vol 0.15M · Avg 0.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
32.1%
avg -27.0%
ROIC
-6.0%
avg -23.8%
ROA
27.7%
avg -17.9%
Analysis
ROE is currently the strongest return metric at 32.1% versus its period average of -27.0%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Nadav Kidron | President, Chief Executive Officer & Executive Chairman | $1.07M | — | 52 | $3.42M | 8.36% |
Miriam Kidron | Chief Scientific Officer & Director | $760,351.00 | — | 86 | $3.42M | 8.36% |
Joshua Hexter | Chief Operating & Business Officer | $583,333.00 | — | 56 | $1.16M | 2.84% |
Avraham Gabay | Chief Financial Officer, Treasurer & Secretary | $303,065.00 | — | 40 | $745,145.00 | 1.82% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$306.63M
MacroGenics, Inc.
NASDAQ:MGNX
$258.41M
Shattuck Labs, Inc.
NASDAQ:STTK
$232.81M
InflaRx N.V.
NASDAQ:IFRX
$130.74M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$125.30M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$90.90M
Coya Therapeutics, Inc.
NASDAQ:COYA
$89.27M
ImageneBio Inc
NASDAQ:IMA
$63.61M
Clene Inc.
NASDAQ:CLNN
$60.71M
Context Therapeutics Inc.
NASDAQ:CNTX
$56.16M
Who manages ORMP?
Oramed Pharmaceuticals Inc. (ORMP) lists 4 active executives. The top listed executive is Miriam Kidron, Chief Scientific Officer & Director.
Are ORMP insiders buying or selling?
Recent insider activity shows net selling of $3.48M.
Explore More
Continue the stock analysis
Jump to another research area for this company.